Vincent Pham to Present at the 2025 San Antonio Liver Cancer Symposium
SAN ANTONIO, TEXAS — The Huang Laboratory at UT Health San Antonio is proud to announce that Vincent Pham, PhD candidate in the Cancer Biology discipline and member of the Huang Lab, will present his research at the 2025 San Antonio Liver Cancer Symposium (SALCS).
The San Antonio Liver Cancer Symposium, hosted annually by the Mays Cancer Center and UT Health San Antonio, brings together leading clinicians, researchers, and industry experts to discuss the latest advances in liver cancer diagnosis, treatment, and translational research. The symposium emphasizes multidisciplinary collaboration aimed at improving outcomes for patients with hepatocellular carcinoma (HCC) and other liver malignancies.
Vincent’s presentation will feature recent preclinical work on PH102, a GPC3-targeted CAR T-cell therapy designed to overcome immune resistance in solid tumors. His research explores how PH102 reprograms the tumor immune microenvironment (TiME) to enhance T-cell infiltration, persistence, and cytotoxicity in advanced hepatocellular carcinoma models. The project represents a collaborative effort between the Huang Lab and Powerhouse Therapeutics Inc, where Vincent also serves as CEO.
As part of the symposium’s scientific program, his presentation reflects UT Health San Antonio’s growing leadership in translational immunotherapy and the Mays Cancer Center’s mission to accelerate breakthroughs in precision cancer medicine through academic–industry partnerships.
The Huang Lab congratulates Vincent on this recognition and is proud to support his ongoing efforts to translate innovative cell-based therapies like PH102 from the bench to the bedside.
About the Huang Lab
The Huang Lab at UT Health San Antonio is a basic and translational cancer research group within the MD Anderson Mays Cancer Center at UT Health San Antonio. Our team integrates hematology and solid tumor biology with immunology and metabolism to uncover mechanisms and design interventions. We advance cell and biologic therapies, including CAR T‑cell approaches for solid tumors. We also conduct research in trauma and military health. We move discoveries toward clinical impact through product development and collaborations with clinicians and industry. Education and mentorship are core to our mission. We train students, postdoctoral fellows, and early‑career scientists in rigorous, multidisciplinary research. Together, we aim to deliver therapies and technologies that improve patient outcomes.